164 related articles for article (PubMed ID: 31508822)
1. Impact of an Upper Respiratory Tract Infection on Botulinum Toxin Efficacy in Spasmodic Dysphonia Patients.
Kirke DN; Kaye R; Blitzer A
Laryngoscope; 2020 Jul; 130(7):1746-1749. PubMed ID: 31508822
[TBL] [Abstract][Full Text] [Related]
2. Quantitative laryngeal electromyography parameters may correlate with improved outcomes following botulinum toxin injection for spasmodic dysphonia.
Dwyer CD; Leclerc AA; Nandedkar SD; Young VN; Rosen CA
Muscle Nerve; 2021 Apr; 63(4):525-530. PubMed ID: 33382480
[TBL] [Abstract][Full Text] [Related]
3. Unilateral versus bilateral botulinum toxin injections in adductor spasmodic dysphonia in a large cohort.
Dharia I; Bielamowicz S
Laryngoscope; 2020 Nov; 130(11):2659-2662. PubMed ID: 31837152
[TBL] [Abstract][Full Text] [Related]
4. Alternating Unilateral Versus Bilateral Injections of Botulinum Toxin for the Treatment of Adductor Spasmodic Dysphonia.
Lee SJ; Kang MS; Choi HS; Lim JY
Otolaryngol Head Neck Surg; 2021 Apr; 164(4):815-820. PubMed ID: 32957836
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of Onabotulinum Toxin A Treatment for Adductor Spasmodic Dysphonia and Laryngeal Tremor.
Patel PN; Kabagambe EK; Starkweather JC; Keller M; Gamsarian V; Lee J; Kulkarni V; Garrett CG; Francis DO
JAMA Otolaryngol Head Neck Surg; 2018 Apr; 144(4):293-299. PubMed ID: 29423509
[TBL] [Abstract][Full Text] [Related]
6. Botulinum Toxin in Secondarily Nonresponsive Patients with Spasmodic Dysphonia.
Mor N; Tang C; Blitzer A
Otolaryngol Head Neck Surg; 2016 Sep; 155(3):458-61. PubMed ID: 27143711
[TBL] [Abstract][Full Text] [Related]
7. Adductor spasmodic dysphonia: Botulinum toxin a injections or laser thyroarytenoid myoneurectomy? A comparison from the patient perspective.
Schuering JHC; Heijnen BJ; Sjögren EV; Langeveld APM
Laryngoscope; 2020 Mar; 130(3):741-746. PubMed ID: 31169922
[TBL] [Abstract][Full Text] [Related]
8. Association of Laryngeal Botulinum Neurotoxin Injection With Work Productivity for Patients With Spasmodic Dysphonia.
Meyer TK; Spiekerman C; Kaye R; Blitzer A; Kamizi RS; Jiang L; Weaver EM
JAMA Otolaryngol Head Neck Surg; 2021 Sep; 147(9):804-810. PubMed ID: 34351425
[TBL] [Abstract][Full Text] [Related]
9. Retrospective review of dosing trends in botulinum toxin injections for the treatment of adductor spasmodic dysphonia in a long-term cohort.
French G; Bosch JD; Randall DR
J Otolaryngol Head Neck Surg; 2020 Jan; 49(1):4. PubMed ID: 31937363
[TBL] [Abstract][Full Text] [Related]
10. Common practices in botulinum toxin injection for spasmodic dysphonia treatment: A national survey.
Shoffel-Havakuk H; Rosow DE; Lava CX; Hapner ER; Johns MM
Laryngoscope; 2019 Jul; 129(7):1650-1656. PubMed ID: 30582627
[TBL] [Abstract][Full Text] [Related]
11. Botulinum Toxin-A Dosing Trends for Adductor Spasmodic Dysphonia at a Single Institution Over 10 Years.
Bradley JP; Barrow EM; Hapner ER; Klein AM; Johns MM
J Voice; 2017 May; 31(3):363-365. PubMed ID: 27839987
[TBL] [Abstract][Full Text] [Related]
12. Relationship of laryngeal botulinum toxin dosage to patient age, vitality, and socioeconomic issues.
Young DL; Halstead LA
J Voice; 2014 Sep; 28(5):614-7. PubMed ID: 24954039
[TBL] [Abstract][Full Text] [Related]
13. Effect of Botulinum Toxin and Surgery among Spasmodic Dysphonia Patients.
van Esch BF; Wegner I; Stegeman I; Grolman W
Otolaryngol Head Neck Surg; 2017 Feb; 156(2):238-254. PubMed ID: 27803079
[TBL] [Abstract][Full Text] [Related]
14. Gender differences in onabotulinum toxin A dosing for adductor spasmodic dysphonia.
Lerner MZ; Lerner BA; Patel AA; Blitzer A
Laryngoscope; 2017 May; 127(5):1131-1134. PubMed ID: 27633917
[TBL] [Abstract][Full Text] [Related]
15. A comparison of the VHI, VHI-10, and V-RQOL for measuring the effect of botox therapy in adductor spasmodic dysphonia.
Morzaria S; Damrose EJ
J Voice; 2012 May; 26(3):378-80. PubMed ID: 20951552
[TBL] [Abstract][Full Text] [Related]
16. Differences in botulinum toxin dosing between patients with adductor spasmodic dysphonia and essential voice tremor.
Orbelo DM; Duffy JR; Hughes Borst BJ; Ekbom D; Maragos NE
J Voice; 2014 Jan; 28(1):123-7. PubMed ID: 24080335
[TBL] [Abstract][Full Text] [Related]
17. Interarytenoid muscle botox injection for treatment of adductor spasmodic dysphonia with vocal tremor.
Kendall KA; Leonard RJ
J Voice; 2011 Jan; 25(1):114-9. PubMed ID: 20137891
[TBL] [Abstract][Full Text] [Related]
18. Botulinum Toxin Dosing Trends in Spasmodic Dysphonia Over a 20-year Period.
Namin AW; Christopher KM; Eisenbeis JF
J Voice; 2017 Jan; 31(1):107-110. PubMed ID: 27005439
[TBL] [Abstract][Full Text] [Related]
19. Factors influencing botulinum toxin dose instability in spasmodic dysphonia patients.
Rosow DE; Pechman A; Saint-Victor S; Lo K; Lundy DS; Casiano RR
J Voice; 2015 May; 29(3):352-5. PubMed ID: 25242042
[TBL] [Abstract][Full Text] [Related]
20. OnabotulinumtoxinA for adductor spasmodic dysphonia (ADSD): Functional results and the role of dosage.
Marchese MR; D'Alatri L; Bentivoglio AR; Paludetti G
Toxicon; 2018 Dec; 155():38-42. PubMed ID: 30315835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
